Don Soland
Director/Board Member chez DBV TECHNOLOGIES
Fortune : 550 235 $ au 31/07/2023
Profil
Daniel B.
Soland is an Independent Director at ACADIA Pharmaceuticals, Inc. and DBV Technologies SA. He previously served as the President & Chief Executive Officer at Epigenesis Pharmaceuticals LLC from 2002 to 2005.
He was also the Chief Executive Officer & Executive Director at uniQure NV in 2016.
Prior to that, he held the position of Director-Worldwide Marketing Operations & VP at Corixa Corp.
and GSK Plc from 1993 to 2002.
He served as a Non-Executive Director at Oxford Biomedica Plc from 2015 to 2016.
Additionally, he has been an Independent Director at KalVista Pharmaceuticals, Inc. since 2019.
Mr. Soland has a background in undergraduate studies from the University of Iowa.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/06/2023 | 28 002 ( 0,02% ) | 517 757 $ | 31/03/2024 | |
DBV TECHNOLOGIES SA
0,02% | 01/08/2023 | 20 000 ( 0,02% ) | 28 750 $ | 31/03/2024 |
ACERAGEN, INC.
0,06% | 19/07/2023 | 4 637 ( 0,06% ) | 3 728 $ | 31/07/2023 |
Postes actifs de Don Soland
| Sociétés | Poste | Début |
|---|---|---|
| DBV TECHNOLOGIES | Director/Board Member | 06/03/2015 |
| ACADIA PHARMACEUTICALS INC. | Director/Board Member | 26/03/2015 |
Anciens postes connus de Don Soland
| Sociétés | Poste | Fin |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Chief Operating Officer | 28/09/2022 |
| KALVISTA PHARMACEUTICALS, INC. | Director/Board Member | 26/05/2022 |
| UNIQURE N.V. | Chief Executive Officer | 22/09/2016 |
| OXFORD BIOMEDICA PLC | Director/Board Member | 05/01/2016 |
| Viropharma, Inc. | Chief Operating Officer | 01/12/2014 |
Formation de Don Soland
| University of Iowa | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| OXFORD BIOMEDICA PLC | Health Technology |
| DBV TECHNOLOGIES | Health Technology |
| UNIQURE N.V. | Health Technology |
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Seqirus Vaccines Ltd.
 Seqirus Vaccines Ltd. BiotechnologyHealth Technology Seqirus Vaccines Ltd. manufactures vaccines. The company is headquartered in Maidenhead, the United Kingdom. | Health Technology |
Epigenesis Pharmaceuticals LLC
 Epigenesis Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Epigenesis Pharmaceuticals LLC develops inhaled respiratory medicines. It also provides treatments for the asthma, obstructive pulmonary disease and other respiratory diseases. The company was founded by Jonathan W. Nyce in 1995 and is headquartered in Cranbury, NJ. | Health Technology |
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | Health Technology |
| Viropharma, Inc. |
